1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Degenerative Disc Disease - Pipeline Review, H1 2017

Degenerative Disc Disease - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 65 pages

Degenerative Disc Disease - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease – Pipeline Review, H1 2017, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 1, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Degenerative Disc Disease - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Degenerative Disc Disease - Overview
Degenerative Disc Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Degenerative Disc Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Degenerative Disc Disease - Companies Involved in Therapeutics Development
AnGes MG Inc
Biogenomics Ltd
Biopharm GmbH
BioRestorative Therapies Inc
Bone Therapeutics SA
DiscGenics Inc
ISTO Technologies Inc
Osiris Therapeutics Inc
Samumed LLC
TissueGene Inc
U.S. Stem Cell Inc
Yuhan Corp
Degenerative Disc Disease - Drug Profiles
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ALLOB - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
AMG-0103 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BRTX-100 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
dibotermin alfa biosimilar - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NuQu - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
OTICR-01 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Poly N-Acetyl Glucosamine Hydrogel - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SM-04690 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
TG-D - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
X-0002 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
YH-14618 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Degenerative Disc Disease - Dormant Projects
Degenerative Disc Disease - Product Development Milestones
Featured News and Press Releases
Feb 08, 2017: BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease
Nov 15, 2016: Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a Potential Treatment for Degenerative Disc Disease
Nov 01, 2016: Samumed to present data on SM-04690 at American College of Rheumatology 2016 Annual Meeting
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Sep 12, 2016: BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells' Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product
Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA
Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA
Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Degenerative Disc Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Degenerative Disc Disease - Pipeline by AnGes MG Inc, H1 2017
Degenerative Disc Disease - Pipeline by Biogenomics Ltd, H1 2017
Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1 2017
Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H1 2017
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2017
Degenerative Disc Disease - Pipeline by DiscGenics Inc, H1 2017
Degenerative Disc Disease - Pipeline by ISTO Technologies Inc, H1 2017
Degenerative Disc Disease - Pipeline by Osiris Therapeutics Inc, H1 2017
Degenerative Disc Disease - Pipeline by Samumed LLC, H1 2017
Degenerative Disc Disease - Pipeline by TissueGene Inc, H1 2017
Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H1 2017
Degenerative Disc Disease - Pipeline by Yuhan Corp, H1 2017
Degenerative Disc Disease - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Degenerative Disc Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.